DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR. et al.
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
Lancet 2016;
387: 1163-77
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.